GlassScriptPhysician profile
Andrew T Thorp
NPI 1013367515
$7,976.77
in general payments reported to CMS, 2019-2025
21 companies · $1,411 in 2025
The $1,411 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,515 · 2020: $278 · 2021: $3,448 · 2022: $141 · 2023: $874 · 2024: $309 · 2025: $1,411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,585 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,585.28 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,296.54 | 2021-2023 | Onyx Frontier |
| Abbott Laboratories | $2,588.05 | 2019-2025 | Jot Dx, Aveir, Diamondback Coronary |
| Novartis Pharmaceuticals Corporation | $340.02 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $205.76 | 2025 | Eliquis, Camzyos |
| Abiomed | $177.56 | 2023 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $156.62 | 2023-2025 | Lifevest |
| Novo Nordisk INC | $153.31 | 2025 | Wegovy |
| Amgen INC. | $151.82 | 2021-2025 | Repatha, Repatha |
| Edwards Lifesciences Corporation | $124.68 | 2024 | |
| Terumo Medical Corporation | $122.82 | 2023 | Angio-Seal |
| Pfizer INC. | $117.82 | 2023-2025 | |
| Cathworks, INC. | $84.12 | 2023 | Ffrangio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.97 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $71.52 | 2025 | |
| Scpharmaceuticals INC. | $66.82 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $63.72 | 2023-2024 | Farxiga |
| Penumbra, INC. | $63.06 | 2023 | Indigo System |
| Shockwave Medical, INC | $46.99 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Acist Medical Systems, INC. | $26.65 | 2024 | |
| Boston Scientific Corporation | $25.00 | 2023 | Avvigo Guidance System |
| Merck Sharp & Dohme LLC | $21.92 | 2025 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Thorp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.